Dementia and Alzheimer Disease

The agent is designed to target the tau “seeds” that spread throughout the brain over the progression of the disease, with its first clinical assessment expected to occur in early 2019.

In quick cognitive tests routinely used in primary care, misclassification by at least 1 assessment occured in 36.7% participants, whereas only 1.7% were misclassified by all 3.

Can amyloid accumulation predict a decline in episodic memory over time?

The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine shared how the previous muscarinic agonists have better informed the development of this investigational agent, VU319.

The positive topline results from Study 201 have led to the initiation of an open-label extension for the subjects previously enrolled in Study 201, which is set to begin later this year.

Neurology News Network for the week of November 17, 2018.

The associate professor at NYU Langone discussed several of the questions that remained unanswered about the relationship between sleep and Alzheimer disease.

The BAN2401 International Project Team Leader and Clinical Lead spoke about how the introduction of a novel, potentially disease modifying therapy would represent a paradigm shift in the field.

The associate professor at NYU Langone discussed emerging evidence that suggests that sleep disruption results in higher levels of markers associated with Alzheimer disease.

The product was being marketed for conditions including Alzheimer disease, fibromyalgia, spinal cord injury, multiple sclerosis, muscular dystrophy, Parkinson disease, and peripheral neuropathy, among others.

The Founder and CEO of NeuroTrials Research spoke about the current landscape of insomnia, noting that lemborexant holds promise as a potential therapy.

The director and chair of the Feil Family Brain & Mind Research Institute at Weill Cornell Medicine provided insight into the different pathologies that lead to this dementia.

The Anne Parrish Titzell Professor of Neurology and Neuroscience at Weill Cornell Medicine’s Feil Family Brain and Mind Research Institute spoke about the cost the condition has for patients and their families.

Neurology News Network for the week of November 10, 2018.

Researchers found a link between atrial fibrillation and an increased risk of dementia and concluded that anticoagulants could help decrease that risk.

The president of the ANA offered his perspective on these novel genetic therapies, as well as other a few other areas of interest.

The professor of psychiatry and neuroscience at the Icahn School of Medicine at Mount Sinai spoke about new study findings that suggest antidiabetic therapy could reduce Alzheimer genetic expression.

Neurology News Network for the week of November 3, 2018.

In clinical trials, differences in the use of cholinesterase inhibitors and memantine between treatment and placebo groups may lead to the conclusion that a treatment is effective when it is not, or vice versa.

Although treatment needs to be assessed in a larger trial, it also showed improvements in 2 measurements of functional ability.

The compromised microvascular and insulin receptor signaling pathways seen in Alzheimer disease have been shown to be reduced or normalized by exposure to antidiabetic therapies.

Trial results showed a reduction of 61% in disease progression in both primary efficacy endpoints measuring cognition and activities of daily living at 14 months.

Striking findings are a call for public policy and research initiatives for aging populations with neurologic conditions.

Zonisamide improved Parkinsonism as an adjunct to levodopa in patients with dementia with Lewy bodies in phase 3 trial.

As well as showing a positive impact on patient daily living and cognitive decline, data also confirmed SIGMAR1 and COMT as biomarkers of response to the therapy.